Q&A: How to attract the eye of an early investor in biotech R&D tools
SAN FRANCISCO — As early-stage biotechs grapple with the funding and IPO challenges associated with a down economy, some adjacent and more recession-proof areas are still seeing robust investments.
Jenny Rooke, founder and managing partner of Genoa Ventures, sat down with Endpoints News yesterday to talk about her investments in early-stage companies that blend biology and technology, but aren’t working on a therapeutic.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.